RNA viruses, a diverse group including influenza, Zika, and SARS-CoV-2, exhibit unique replication strategies that present both challenges and opportunities for understanding and combating Viral Infections. One characteristic feature is their high mutation rate due to the error-prone nature of RNA-dependent RNA polymerases. This rapid mutation can lead to the emergence of new viral variants, impacting the efficacy of vaccines and antiviral therapies. RNA Virus Replication begins with the attachment and entry of the virus into host cells. Once inside, the viral RNA is released, and replication complexes are formed to facilitate the synthesis of new RNA genomes. Positive-sense RNA viruses can directly translate their genomic RNA into proteins, while negative-sense RNA viruses must first transcribe complementary RNA strands for translation. The assembly of new viral particles occurs in the host cell's cytoplasm, followed by the release of mature virions. The challenge in targeting RNA Virus Replication lies in the diversity of the viral enzymes and proteins involved. Antiviral Drugs often aim to disrupt specific steps in the replication cycle, such as viral entry, genome replication, or protein synthesis. However, the constant evolution of RNA viruses poses hurdles for drug development, emphasizing the need for ongoing research and surveillance to stay ahead of emerging viral threats.